[Induction polychemotherapy of non-Hodgkin's lymphomas in children].
The effectiveness of a new procedure of inductive polychemotherapy (vincristine, cyclophosphamide, adriamycin and prednisolone) was studied in 60 non-pretreated cases of pediatric non-Hodgkin's lymphoma. The treatment was given in 7-day courses. Remission was registered in 46 out of 60 patients (76.6%). Complete regression of symptoms was observed in 58.3%. A three-year survival rate in the entire study group was 28%; the highest rate (39%) was recorded in abdominal involvement group. Due to slight toxicity the scheme should be recommended for a large-scale integration with practice.
D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000473:pathology; D000293:Adolescent; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy / Q000401:mortality; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
Induktivnaia polikhimioterapiia nekhodzhkinskikh limfom u deteĭ.